Evidence map›Paper›PMID 34589716›Full record

ArticleBlood cancer discovery2021

A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors.

David J Young, Bao Nguyen, Li Li, Tomoyasu Higashimoto, Mark J Levis, Jun O Liu, Donald Small

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. American journal of cancer research · 2023
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

David J YoungDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-0885-8568
Bao NguyenDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Li LiDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Tomoyasu HigashimotoDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-0435-065X
Mark J LevisDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Jun O LiuDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Donald SmallDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. donsmall@jhmi.edu.
Johns Hopkins University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
LAB RESEARCH TRAINING IN PEDIATRIC ONCOLOGY-HEMATOLOGYT32CA060441 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN D FRIEDMAN · 1993 to 2026
$14.9M
Postdoctoral Medical Genetics Training GrantT32GM007471 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI TAO WANG · 1985 to 2026
$8.0M
FLT3 Tyrosine Kinase Inhibitors As Therapy for LeukemiaR01CA090668 · NCI · JOHNS HOPKINS UNIVERSITY · PI SMALL, DONALD · 2002 to 2018
$5.0M
NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA090668NCI NIH HHS T32 CA060441NIGMS NIH HHS T32 GM007471
6 · The paper itself

Abstract

FMS-like tyrosine kinase 3 (FLT3) is the most frequently-mutated gene in acute myeloid leukemia and a target for tyrosine kinase inhibitors (TKI). FLT3 TKI have yielded limited improvements to clinical outcomes. One reason for this is TKI inhibition by endogenous factors. We characterized plasma protein binding of FLT3 TKI, specifically staurosporine-derivatives (STS-TKI) by alpha-1-acid glycoprotein (AGP); simulating its effects upon drug efficacy. Human AGP inhibits the anti-proliferative activity of STS-TKI in FLT3-ITD-dependent cells, with IC

Indexed as

Leukemia, Myeloid, AcuteProtein Kinase InhibitorsAnimalsBlood Proteinsfms-Like Tyrosine Kinase 3MiceBlood Proteinsfms-Like Tyrosine Kinase 3Protein Kinase InhibitorsAcute myeloid leukemiaAlpha-1-acid glycoproteinCombinatorial drug therapyFMS-like tyrosine kinase 3Tyrosine kinase inhibitor

Identifiers

PMID34589716
PMCPMC8478262
OpenAlexW3173437529

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.